Clinical Trial Update: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the immunogenicity of metreleptin in patients with generalized lipodystrophy; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Lipodystrophy

Drugs mentioned

• MYALEPT (METRELEPTIN)

Snippet

Sponsor: Aegerion Pharmaceuticals, Inc. | Conditions: Generalized Lipodystrophy | Phase 4 | Status: COMPLETED | Results posted: 2025-11-26